K
42.26
0.43 (1.03%)
| Penutupan Terdahulu | 41.83 |
| Buka | 41.83 |
| Jumlah Dagangan | 222,300 |
| Purata Dagangan (3B) | 501,298 |
| Modal Pasaran | 3,203,128,576 |
| Harga / Pendapatan (P/E TTM) | 93.91 |
| Harga / Pendapatan (P/E Ke hadapan) | 29.15 |
| Harga / Jualan (P/S) | 5.05 |
| Harga / Buku (P/B) | 5.58 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 28 Oct 2025 |
| Margin Keuntungan | -3.52% |
| Margin Operasi (TTM) | 9.63% |
| EPS Cair (TTM) | -0.240 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 72.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2.17% |
| Nisbah Semasa (MRQ) | 3.66 |
| Aliran Tunai Operasi (OCF TTM) | 44.03 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 25.15 M |
| Pulangan Atas Aset (ROA TTM) | -1.77% |
| Pulangan Atas Ekuiti (ROE TTM) | -3.81% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Menaik |
| Drug Manufacturers - Specialty & Generic (Global) | Menaik | Menaik | |
| Stok | Kiniksa Pharmaceuticals, Ltd. | Bercampur | Menaik |
AISkor Stockmoo
-0.4
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | -0.40 |
|
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 3.80% |
| % Dimiliki oleh Institusi | 97.31% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Fairmount Funds Management Llc | 30 Sep 2025 | 1,772,839 |
| Parkman Healthcare Partners Llc | 30 Sep 2025 | 671,592 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 55.00 (Goldman Sachs, 30.15%) | Beli |
| Median | 52.50 (24.23%) | |
| Rendah | 50.00 (Wedbush, 18.32%) | Beli |
| Purata | 52.50 (24.23%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 37.99 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Wedbush | 13 Jan 2026 | 50.00 (18.32%) | Beli | 38.60 |
| Goldman Sachs | 29 Oct 2025 | 55.00 (30.15%) | Beli | 37.38 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 12 Jan 2026 | Pengumuman | Kiniksa Pharmaceuticals Provides Corporate Update |
| 07 Jan 2026 | Pengumuman | Kiniksa Pharmaceuticals to Present at 44th Annual J.P. Morgan Healthcare Conference |
| 12 Nov 2025 | Pengumuman | Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in London |
| 28 Oct 2025 | Pengumuman | Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |